Korro Bio Overview
- Founded
- 2018
- Status
- Private
- Employees
- 69
- Latest Deal Type
- Series B
- Latest Deal Amount
- $116M
- Investors
- 16
Korro Bio General Information
Description
Developer of transformative RNA therapeutics designed to treat patients with rare and debilitating diseases by addressing the underlying genetic cause. The company's platform offers transformative treatments and utilizes the precision provided by nucleic acid-based therapeutics to target responsible sequences within the genetic code, enabling healthcare providers to treat patients with rare genetic diseases.
Contact Information
Website
www.korrobio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- One Kendall Square
- Building 600-700, Suite 6-401
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Korro Bio Timeline
Korro Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 05-Jan-2022 | $116M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Early Stage VC (Series A) | 10-Sep-2020 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 2. Seed Round | $10M | $14M | 0000 | Completed | Generating Revenue | |
| 1. Seed Round | 06-Jun-2019 | $4M | $4M | 0000 | Completed | Generating Revenue |
Korro Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series B-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed 3 | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Seed 2 | 2,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 1.76% |
| Seed 1 | 4,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 3.53% |
Korro Bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of transformative RNA therapeutics designed to treat patients with rare and debilitating diseases by addressin
Drug Discovery
Cambridge, MA
69
As of 2021
00000
0000
0000-00-00
00000000000
00000
0000000
erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
0000 000000000
Seattle, WA
000
As of 0000
00000
0000
0000-00-00
00000000000
00000
0000000
at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla par
0000 000000000
Cambridge, MA
0000
As of 0000
00.000
0000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialKorro Bio Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ShapeTX | Venture Capital-Backed | Seattle, WA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
| 0000 0000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly PE-Backed | Cambridge, MA | 000 | 00000 | 000000000 | |
| 0000000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
Korro Bio Patents
Korro Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210380980-A1 | Methods and compositions for the adar-mediated editing of serpina1 | Pending | 28-May-2020 | 0000000000 | |
| AU-2020210900-A1 | Rna-editing oligonucleotides and uses thereof | Pending | 22-Jan-2019 | 000000000 | |
| AU-2020210645-A1 | Rna-editing oligonucleotides and uses thereof | Pending | 22-Jan-2019 | 00000000000 | |
| AU-2020211949-A1 | Rna-editing oligonucleotides and uses thereof | Pending | 22-Jan-2019 | 00000000000 | |
| CA-3126947-A1 | Rna-editing oligonucleotides and uses thereof | Pending | 22-Jan-2019 | C12N15/11 |
Korro Bio Executive Team (8)
Korro Bio Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Silverstein | Self | Board Member | 000 0000 |
| Ali Behbahani MD | Self | Board Member | 000 0000 |
| Colin Walsh Ph.D | Qiming Venture Partners | Board Member | 000 0000 |
| Hannah Chang Ph.D | Wu Capital | Board Member | 000 0000 |
| Jean-Francois Formela MD | Self | Co-Founder & Board Member | 000 0000 |
Korro Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKorro Bio Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Eventide Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Fidelity Management & Research | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Monashee Investment Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Point72 Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sixty Degree Capital | Venture Capital | Minority | 000 0000 | 000000 0 |